Recurrent vitreous haemorrhage after primary vitrectomy has been reported in up to 80% of eyes over a six month period.15 Since the postoperative haemorrhage usually occurs within the first few days after surgery, the VEGF blockade provided by a single dose of bevacizumab for four weeks is sufficient to prevent postoperative bleeding in the vast majority of cases.12 This was observed in this study with very low incidence of post-operative vitreous haemorrhage. The gene discussed is VEGFA; the disease is vitreous hemorrhage.